Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Knuf

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Monatsschrift Kinderheilkunde : Organ Der Deutschen Gesellschaft Fur Kinderheilkunde|December 23, 2020
[Use of masks by children to prevent infection with SARS-CoV-2]Hans-Iko Huppertz, Reinhard Berner, Renate Schepker, et al.
Klinische Monatsblatter Fur Augenheilkunde|November 9, 2017
[Evaluation of Ophthalmic Follow-up Care of Former Pre-term and Full-term Infants Aged from 4 to 10 Years in Germany - Results of the Wiesbaden Prematurity Study (WPS)]Achim Fieß, Ruth Kölb-Keerl, Heike Maria Elflein, et al.
The Pediatric Infectious Disease Journal|September 13, 2011
Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infantsMarkus Knuf, Heidemarie Pankow-Culot, Detlef Grunert, et al.
The New England Journal of Medicine|October 15, 2011
Oil-in-water emulsion adjuvant with influenza vaccine in young childrenTimo Vesikari, Markus Knuf, Peter Wutzler, et al.
Vaccine|December 3, 2014
Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of ageMarkus Knuf, Geert Leroux-Roels, Hans C Rümke, et al.
Vaccines|June 25, 2026
Vaccination Against Serogroup B Meningococcal Disease: Current Status and Future Perspectives-A Consensus Document of the World Association for Infectious Diseases and Immunological Disorders (WAidid)Susanna Esposito, Nigel Curtis, Ulrich Heininger, et al.
The Pediatric Infectious Disease Journal|January 6, 2006
Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy childrenMarkus Knuf, Pirmin Habermehl, Fred Zepp, et al.
The Pediatric Infectious Disease Journal|May 9, 2007
Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhoodJoerg Faber, Therese Schuessler, Adam Finn, et al.
The Pediatric Infectious Disease Journal|July 1, 2014
Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of ageMarkus Knuf, Geert Leroux-Roels, Hans C Rümke, et al.
European Journal of Pediatrics|January 12, 2013
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled studyMarkus Knuf, Olivier Romain, Klaus Kindler, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Monatsschrift Kinderheilkunde : Organ Der Deutschen Gesellschaft Fur Kinderheilkunde|December 23, 2020
[Use of masks by children to prevent infection with SARS-CoV-2]Hans-Iko Huppertz, Reinhard Berner, Renate Schepker, et al.
Klinische Monatsblatter Fur Augenheilkunde|November 9, 2017
[Evaluation of Ophthalmic Follow-up Care of Former Pre-term and Full-term Infants Aged from 4 to 10 Years in Germany - Results of the Wiesbaden Prematurity Study (WPS)]Achim Fieß, Ruth Kölb-Keerl, Heike Maria Elflein, et al.
The Pediatric Infectious Disease Journal|September 13, 2011
Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infantsMarkus Knuf, Heidemarie Pankow-Culot, Detlef Grunert, et al.
The New England Journal of Medicine|October 15, 2011
Oil-in-water emulsion adjuvant with influenza vaccine in young childrenTimo Vesikari, Markus Knuf, Peter Wutzler, et al.
Vaccine|December 3, 2014
Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of ageMarkus Knuf, Geert Leroux-Roels, Hans C Rümke, et al.
Vaccines|June 25, 2026
Vaccination Against Serogroup B Meningococcal Disease: Current Status and Future Perspectives-A Consensus Document of the World Association for Infectious Diseases and Immunological Disorders (WAidid)Susanna Esposito, Nigel Curtis, Ulrich Heininger, et al.
The Pediatric Infectious Disease Journal|January 6, 2006
Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy childrenMarkus Knuf, Pirmin Habermehl, Fred Zepp, et al.
The Pediatric Infectious Disease Journal|May 9, 2007
Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhoodJoerg Faber, Therese Schuessler, Adam Finn, et al.
The Pediatric Infectious Disease Journal|July 1, 2014
Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of ageMarkus Knuf, Geert Leroux-Roels, Hans C Rümke, et al.
European Journal of Pediatrics|January 12, 2013
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled studyMarkus Knuf, Olivier Romain, Klaus Kindler, et al.
Pageof 12